UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Annals of oncology, 2017-10, Vol.28 (10), p.2443

2017

Volltextzugriff (PDF)

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.1636-1646

2020

Volltextzugriff (PDF)

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

The New England journal of medicine, 2023-11, Vol.389 (22), p.2039-2051

2023

Volltextzugriff (PDF)

Diselenide–Pemetrexed Assemblies for Combined Cancer Immuno‐, Radio‐, and Chemotherapies

Angewandte Chemie International Edition, 2020-02, Vol.59 (7), p.2700-2704

International ed. in English, 2020

Volltextzugriff (PDF)

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.124-129

2019

Volltextzugriff (PDF)

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1505-1517

2020

Volltextzugriff (PDF)

A firm asymptomatic erythematous nodule on the temple

Indian journal of dermatology, 2021-09, Vol.66 (5), p.577

2021

Volltextzugriff (PDF)

A multimodal Metal-Organic framework based on unsaturated metal site for enhancing antitumor cytotoxicity through Chemo-Photodynamic therapy

Journal of colloid and interface science, 2022-09, Vol.621, p.180-194

2022

Volltextzugriff (PDF)

Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials

Journal of chemotherapy (Florence), 2023-02, Vol.35 (2), p.158-162

2023

Volltextzugriff (PDF)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Volltextzugriff (PDF)

Besonderheiten in der Therapie des TTF-1-negativen Adenokarzinoms der Lunge

Pneumologie (Stuttgart, Germany), 2023-01, Vol.77 (7), p.426-429

2023

Volltextzugriff (PDF)

Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative

International journal of nanomedicine, 2019-01, Vol.14, p.6339-6356

2019

Volltextzugriff (PDF)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Annals of oncology, 2016-07, Vol.27 (7), p.1286-1291

2016

Volltextzugriff (PDF)

Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study

British journal of clinical pharmacology, 2023-02, Vol.89 (2), p.699-704

2023

Volltextzugriff (PDF)

miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial-Mesenchymal Transition

International journal of molecular sciences, 2022-12, Vol.23 (23), p.15352

2022

Volltextzugriff (PDF)

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)

Journal of clinical oncology, 2020-03, Vol.38 (8), p.793-803

2020

Volltextzugriff (PDF)

Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations

Anti-cancer drugs, 2022-01, Vol.33 (1), p.e584-e589

2022

Volltextzugriff (PDF)

Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model

European journal of pharmaceutical sciences, 2016-01, Vol.81, p.60-66

2016

Volltextzugriff (PDF)

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis

Journal of thoracic oncology, 2020-01, Vol.15 (1), p.91-100

2020

Volltextzugriff (PDF)

Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy

Biomaterials, 2022-01, Vol.280, p.121321-121321, Article 121321

2022

Volltextzugriff (PDF)

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2187-2196

2020

Volltextzugriff (PDF)

Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed

Journal of controlled release, 2015-12, Vol.220 (Pt A), p.29-36

2015

Volltextzugriff (PDF)

Malignant Pleural Mesothelioma: State of the art and advanced cell therapy

European journal of medicinal chemistry, 2017-12, Vol.142, p.266-270

2017

Volltextzugriff (PDF)

1 – 25 von 4.497

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.655)
Mit Volltextzugriff
(3.613)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Pemetrexed
(3.909)
Science & Technology
(3.268)
Life Sciences & Biomedicine
(3.168)
Humans
(2.591)
Oncology
(2.241)
Chemotherapy
(1.654)
Lung Neoplasms - Drug Therapy
(1.458)
Guanine - Analogs & Derivatives
(1.371)
Female
(1.367)
Male
(1.320)
Lung Cancer
(1.268)
Middle Aged
(1.165)
Aged
(1.130)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(1.117)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1.047)
Cancer
(971)
Lung Neoplasms - Pathology
(826)
Tumors
(812)
Care And Treatment
(787)
Cancer Therapies
(764)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.665)
EZB Electronic Journals Library
(2.543)
Ingenta
(1.926)
Journals@Ovid Full Text
(1.396)
IngentaConnect Journals
(1.164)
Elsevier ScienceDirect Journals Complete
(685)
Nexis Uni
(585)
Springer Online Journals
(552)
Publisher or Other Site
(537)
Wiley Online Library Journals
(368)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(350)
Taylor & Francis Journals
(344)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(255)
Taylor & Francis Current Content Access
(139)
Wiley Online Library Full Collection 2018
(118)
Taylor & Francis Online
(100)
Nature
(79)
SAGE Journals
(57)
SpringerLink Series
(49)
Oxford Journals
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(17)
... seit 90 Tagen
(73)

Menü

Weitere Dienste

Einstellungen

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Diselenide–Pemetrexed Assemblies for Combined Cancer Immuno‐, Radio‐, and Chemotherapies

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

A firm asymptomatic erythematous nodule on the temple

A multimodal Metal-Organic framework based on unsaturated metal site for enhancing antitumor cytotoxicity through Chemo-Photodynamic therapy

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Besonderheiten in der Therapie des TTF-1-negativen Adenokarzinoms der Lunge

Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study

miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial-Mesenchymal Transition

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)

Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations

Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis

Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed

Malignant Pleural Mesothelioma: State of the art and advanced cell therapy

Suchergebnisse filtern